FAK Inhibition Unlocks Immune Response Against Treatment-Resistant Ovarian Cancer
核心洞察
UC San Diego researchers discovered that blocking focal adhesion kinase (FAK (搜索)) can reprogram immune cells to fight high-grade serous ovarian cancer by releasing omega-3 fatty acids.
The treatment causes macrophages to switch into anti-tumor mode and release CXCL13 (搜索), which attracts tumor-fighting immune cells to create protective immune structures.
In mouse models, combining FAK (搜索) inhibitors with low-dose chemotherapy and immunotherapy significantly suppressed tumor growth and extended survival.
Researchers at the University of California San Diego and Sanford Burnham Prebys Medical Discovery Institute have identified a promising new strategy to overcome immunotherapy resistance in high-grade serous ovarian cancer (HGSOC), the most aggressive and treatment-resistant form of ovarian cancer. Published in Cell Reports, the study reveals how inhibiting focal adhesion kinase (FAK (搜索)) can reprogram the tumor microenvironment to unleash the immune system's anti-cancer potential.
Breaking Through Immune Suppression
High-grade serous ovarian cancer affects over 75% of ovarian cancer patients and remains notoriously difficult to treat due to sophisticated immune evasion mechanisms. While immune checkpoint therapies have revolutionized treatment for many cancers, they have shown limited benefit in ovarian cancer because tumors create an immunosuppressive environment that weakens the body's natural immune response.
"Our findings reveal a previously unrecognized lipid-based communication pathway between ovarian tumors and the immune system," said senior author David D. Schlaepfer, PhD, professor of obstetrics, gynecology and reproductive sciences at UC San Diego School of Medicine. "By inhibiting FAK (搜索), we can re-educate macrophages to promote anti-tumor immunity rather than suppress it."
Novel Mechanism of Action
The research team discovered that FAK (搜索), which is overexpressed in more than 75% of HGSOC cases due to genetic mutations, serves as a critical protective mechanism for ovarian tumors. Its abundance correlates strongly with reduced patient survival, making it an attractive therapeutic target.
When researchers blocked FAK (搜索) activity in ovarian cancer cells, they observed a cascade of immune-activating events:
- Tumor cells release tiny particles containing omega-3 fatty acids, the same healthy fats found in fish oil
- These particles are absorbed by nearby immune cells called macrophages, acting as cellular signals
- The omega-3 signals cause macrophages to switch from an immunosuppressive to an anti-tumor mode
- Reprogrammed macrophages release CXCL13, a chemokine that attracts tumor-fighting T and B cells
- Infiltrating immune cells form tertiary lymphoid structures that act as "immune forward operating bases" within the tumor
Promising Preclinical Results
Using sophisticated mouse models that mimic aggressive, chemotherapy-resistant ovarian tumors with genetic parallels to human HGSOC, the research team tested various treatment combinations. The results were striking: combining an FAK (搜索) inhibitor with low-dose chemotherapy and immunotherapy achieved superior tumor control, significantly increased survival, and enhanced recruitment of lymphocytic populations within the tumor microenvironment.
The triple combination therapy not only suppressed tumor growth but also transformed immunologically "cold" ovarian tumors into "hot" lesions more susceptible to immune attack. This represents a fundamental shift in the tumor microenvironment from immune-suppressing to immune-activating.
Clinical Translation Potential
The discovery has immediate translational relevance, as FAK (搜索)-targeting drugs are already being tested in clinical trials for ovarian cancer, including an ongoing Phase II trial (NCT06014528). The new findings suggest that combining these drugs with immunotherapy and selected chemotherapy may significantly enhance treatment effectiveness.
Kevin Tharp, PhD, co-lead author from Sanford Burnham Prebys, emphasizes the paradigm-shifting role of macrophages in this approach. "Rather than their classical phagocytic role, these resident peritoneal macrophages take on an essential communicative function when reprogrammed, becoming central architects of a robust adaptive immune response," he explained.
Metabolic-Immune Interface
The study also highlights a novel metabolic-immune interface, with omega-3 fatty acid release following FAK (搜索) inhibition serving as a biochemical trigger for macrophage activation. This discovery spotlights nutritional and metabolic pathways as potential adjunct therapeutic targets, potentially expanding treatment options beyond conventional cytotoxic agents.
Future Directions
While the findings offer new hope for patients with treatment-resistant ovarian cancer, the authors note that further investigation is needed to fully characterize the molecular mechanisms, optimize combination therapies, and validate efficacy across diverse patient-derived tumor models. The mechanistic clarity gained, however, provides a solid foundation for imminent clinical trials aimed at harnessing FAK (搜索) inhibition to overcome immune surveillance barriers in ovarian cancer.
Given the poor prognosis and limited treatment options for patients with metastatic HGSOC, this combined approach addresses a critical unmet clinical need and opens the door to improved outcomes through strategic immune modulation. The research exemplifies how targeting metabolic signaling within tumor cells can be intricately linked to immune activation, reinforcing the importance of integrative approaches in designing next-generation cancer therapies.